Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

131 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Among authors: bargou r. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC. Dreier T, et al. Among authors: bargou rc. J Immunol. 2003 Apr 15;170(8):4397-402. doi: 10.4049/jimmunol.170.8.4397. J Immunol. 2003. PMID: 12682277
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA. Hoffmann P, et al. Among authors: bargou r. Int J Cancer. 2005 May 20;115(1):98-104. doi: 10.1002/ijc.20908. Int J Cancer. 2005. PMID: 15688411
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA. Schlereth B, et al. Among authors: bargou r. Cancer Immunol Immunother. 2006 May;55(5):503-14. doi: 10.1007/s00262-005-0001-1. Epub 2005 Jul 20. Cancer Immunol Immunother. 2006. PMID: 16032400
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R. Brandl C, et al. Among authors: bargou r. Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. doi: 10.1007/s00262-007-0298-z. Epub 2007 Feb 20. Cancer Immunol Immunother. 2007. PMID: 17310380
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Bargou R, et al. Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545. Science. 2008. PMID: 18703743 Clinical Trial.
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC. d'Argouges S, et al. Among authors: bargou rc. Leuk Res. 2009 Mar;33(3):465-73. doi: 10.1016/j.leukres.2008.08.025. Epub 2008 Oct 2. Leuk Res. 2009. PMID: 18835037
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA, Kufer P, Bargou R. Baeuerle PA, et al. Among authors: bargou r. Curr Opin Mol Ther. 2009 Feb;11(1):22-30. Curr Opin Mol Ther. 2009. PMID: 19169956 Review.
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Nagorsen D, et al. Among authors: bargou r. Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Leuk Lymphoma. 2009. PMID: 19455460 Review.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC. Topp MS, et al. Among authors: bargou rc. J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
131 results
Jump to page
Feedback